UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model

Biopharmaceutics & drug disposition, 2001-09, Vol.22 (6), p.251-261

2001

Volltextzugriff (PDF)

Phase I study of sunitinib with irinotecan/5-fluorouracil/ leucovorin (FOLFIRI) for advanced gastroesophageal cancers

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS201-TPS201

2010

Volltextzugriff (PDF)

Pharmacokinetics of paclitaxel-containing liposomes in rats

AAPS PharmSci, 2003-11, Vol.5 (4), p.E32-100

2003

Volltextzugriff (PDF)

Understanding the role of carbonyl reductase polymorphisms on doxorubicin-induced cardiotoxicity with population pharmacokinetics (PK)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.2606-2606

2011

Volltextzugriff (PDF)

Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose

Antimicrobial Agents and Chemotherapy, 2005-01, Vol.49 (1), p.148-152

2005

Volltextzugriff (PDF)

A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3024-3024

2010

Volltextzugriff (PDF)

Enhanced gemcitabine (G) exposure in combination with escalating doses of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] (P) in patients with advanced malignancies

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13031-e13031

2010

Volltextzugriff (PDF)

Utilizing mechanistic PK/PD modeling to simultaneously examine free CCL2, total CCL2, and CNTO 888 serum concentration time data

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3029-3029

2010

Volltextzugriff (PDF)

Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3034-3034

2011

Volltextzugriff (PDF)

Application of mechanism-based PKPD model to identify optimal dosing regimens for future development of oraxol

Journal of clinical oncology, 2013, Vol.31 (15_suppl), p.e13505-e13505

2013

Volltextzugriff (PDF)

A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e15540-e15540

2009

Volltextzugriff (PDF)

Pharmacokinetics of oral deforolimus (AP23573, MK-8669)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.14555-14555

2008

Volltextzugriff (PDF)

Mechanism-based PKPD model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET- 743) treatment

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.2545-2545

2007

Volltextzugriff (PDF)

OT1-03-03: Effect of Tamoxifen Therapy on Inhibition of Tumor Suppressor p53 by Estrogen Receptor

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.OT1-03-03-OT1-03-03

2011

Volltextzugriff (PDF)

Modeling and simulation of neutropenia to support dosing regimens for liposome-encapsulated paclitaxel easy-to-use (LEP- ETU)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.13011-13011

2007

Volltextzugriff (PDF)

Results of a clinical pharmacokinetic (PK) bioequivalence (BE) study of liposomal paclitaxel (LEP-ETU) versus paclitaxel (T) in patients with advanced cancer

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.2017-2017

2006

Volltextzugriff (PDF)

Final results of a Phase I study of Liposome Entrapped Paclitaxel (LEP-ETU) in patients with advanced cancer

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.2048-2048

2005

Volltextzugriff (PDF)

Final results of a phase I study of liposome encapsulated SN-38 (LE-SN38): Safety, pharmacogenomics, pharmacokinetics, and tumor response

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.2017-2017

2005

Volltextzugriff (PDF)

Development of a pharmacokinetic (PK) model and assessment of patient (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I trials of AP23573 (AP), a mTOR inhibitor

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3043-3043

2005

Volltextzugriff (PDF)

Pharmacogenomic and pharmacokinetic assessment of liposome encapsulated SN-38 (LE-SN38) in advanced cancer patients

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.2501-2501

2004

Volltextzugriff (PDF)

Pharmacogenomic and pharmacokinetic assessment of liposome encapsulated SN-38 (LE-SN38) in advanced cancer patients

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.2501-2501

2004

Volltextzugriff (PDF)

Noncovalent dimerization of paclitaxel in solution: Evidence from electrospray ionization mass spectrometry

Journal of pharmaceutical sciences, 2002-09, Vol.91 (9), p.2057-2066

2002

Volltextzugriff (PDF)

Delineation of an insula-BNST circuit engaged by struggling behavior that regulates avoidance in mice

Nature communications, 2021-06, Vol.12 (1), p.3561-3561, Article 3561

2021

Volltextzugriff (PDF)

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Clinical cancer research, 2017-07, Vol.23 (14), p.3638-3648

2017

Volltextzugriff (PDF)

Ketamine and MAG Lipase Inhibitor-Dependent Reversal of Evolving Depressive-Like Behavior During Forced Abstinence From Alcohol Drinking

Neuropsychopharmacology (New York, N.Y.), 2016-07, Vol.41 (8), p.2062-2071

2016

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(46)
Tagungsberichte
(3)

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(16)
Humans
(11)
Male
(10)
Female
(7)
Middle Aged
(7)
Oncology
(7)
Pharmacology & Pharmacy
(7)
Animals
(6)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Pharmacology. Drug Treatments
(6)
Adult
(5)
Aged
(5)
Antineoplastic Agents
(5)
Medicine
(5)
Medicine & Public Health
(5)
Tumors
(5)
Aged, 80 And Over
(3)
Antineoplastic Combined Chemotherapy Protocols - Pharmacokinetics
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model

Phase I study of sunitinib with irinotecan/5-fluorouracil/ leucovorin (FOLFIRI) for advanced gastroesophageal cancers

Pharmacokinetics of paclitaxel-containing liposomes in rats

Understanding the role of carbonyl reductase polymorphisms on doxorubicin-induced cardiotoxicity with population pharmacokinetics (PK)

Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose

A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors

Enhanced gemcitabine (G) exposure in combination with escalating doses of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] (P) in patients with advanced malignancies

Utilizing mechanistic PK/PD modeling to simultaneously examine free CCL2, total CCL2, and CNTO 888 serum concentration time data

Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib

Application of mechanism-based PKPD model to identify optimal dosing regimens for future development of oraxol

A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC)

Pharmacokinetics of oral deforolimus (AP23573, MK-8669)

Mechanism-based PKPD model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET- 743) treatment

OT1-03-03: Effect of Tamoxifen Therapy on Inhibition of Tumor Suppressor p53 by Estrogen Receptor

Modeling and simulation of neutropenia to support dosing regimens for liposome-encapsulated paclitaxel easy-to-use (LEP- ETU)

Results of a clinical pharmacokinetic (PK) bioequivalence (BE) study of liposomal paclitaxel (LEP-ETU) versus paclitaxel (T) in patients with advanced cancer

Final results of a Phase I study of Liposome Entrapped Paclitaxel (LEP-ETU) in patients with advanced cancer

Final results of a phase I study of liposome encapsulated SN-38 (LE-SN38): Safety, pharmacogenomics, pharmacokinetics, and tumor response

Development of a pharmacokinetic (PK) model and assessment of patient (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I trials of AP23573 (AP), a mTOR inhibitor

Pharmacogenomic and pharmacokinetic assessment of liposome encapsulated SN-38 (LE-SN38) in advanced cancer patients

Pharmacogenomic and pharmacokinetic assessment of liposome encapsulated SN-38 (LE-SN38) in advanced cancer patients

Noncovalent dimerization of paclitaxel in solution: Evidence from electrospray ionization mass spectrometry

Delineation of an insula-BNST circuit engaged by struggling behavior that regulates avoidance in mice

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Ketamine and MAG Lipase Inhibitor-Dependent Reversal of Evolving Depressive-Like Behavior During Forced Abstinence From Alcohol Drinking

Suchergebnisse filtern